Loading…
Reported covered position: Legal Fellow and Counsel, Senate Committee on Judiciary
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patients' Access to Treatments Act of 2012
Client: VIROPHARMA INCORPORATED · Firm: VIROPHARMA INCORPORATED
340B Drug Pricing Program; Accelerated approval; Antibiotic incentives; Bioequivalence of locally acting drugs; Drug safety/supply chain integrity; Drug shortages; Essential health benefits; Medicaid coverage; Medicare coverage and reimbursement; Orphan Drug Act; Federal grants for drug development; and H.R. 4209, Patients Access to Treatments Act of 2012 (entire bill).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2014 · first_quarter · 1T
Medicaid Outpatient Drug Rebate Program, Orphan Drug Act, Essential Health Benefits, Medicaid coverage, ODA Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2013 · fourth_quarter · Q4
Source: Senate LDA
Medicaid Outpatient Drug Rebate Program, Patient Centered Outcomes Research Institute, Orphan Drug Act, Essential Health Benefits, Medicaid coverage, track and trace/drug pedigree, ODA Tax Credit, and rare disease clinical development; Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2013 · third_quarter · Q3
Medicaid Outpatient Drug Rebate Program, Patient Centered Outcomes Research Institute, Orphan Drug Act, Essential Health Benefits, Medicaid coverage, track and trace/drug pedigree, ODA Tax Credit, and rare disease clinical development.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2013 · second_quarter · Q2
Medicaid Outpatient Drug Rebate Program, Patient Centered Outcomes Research Institute, Orphan Drug Act, Essential Health Benefits, Pre-Existing Condition Insurance Plan Program, Medicaid coverage, track and trace/drug pedigree, ODA Tax Credit, and rare disease clinical development.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2013 · first_quarter · Q1
Medicaid Outpatient Drug Rebate Program, Patient Centered Outcomes Research Institute, Orphan Drug Act, Essential Health Benefits, Annual Branded Prescription Drug Fee, and Pre-Existing Condition Insurance Plan Program.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2012 · fourth_quarter · Q4
Antibiotic incentives, essential health benefits, Federal grants for drug development, annual branded pharmaceutical fee, and Orphan Drug Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2012 · second_quarter · 2A
340B Drug Pricing Program, accelerated approval, antibiotic incentives, bioequivalence of locally acting drugs, drug safety/supply chain integrity, drug shortages, essential health benefits, Medicaid coverage, Medicare coverage and reimbursement, and Orphan Drug Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2012 · third_quarter · Q3
340B Drug Pricing Program; Accelerated approval; Antibiotic incentives; Bioequivalence of locally acting drugs; Drug safety/supply chain integrity; Drug shortages; Essential health benefits; Medicaid coverage; Medicare coverage and reimbursement; Orphan Drug Act; Federal grants for drug development; and H.R. 4209, Patients Access to Treatments Act of 2012 (entire bill).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2012 · second_quarter · Q2
340B Drug Pricing Program, accelerated approval, antibiotic incentives, bioequivalence of locally acting drugs, drug safety/supply chain integrity, drug shortages, essential health benefits, Medicaid coverage, Medicare coverage and reimbursement, and Orphan Drug Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2012 · first_quarter · Q1
340B Drug Pricing Program, accelerated approval, antibiotic incentives, bioequivalence of locally acting drugs, drug safety/supply chain integrity, drug shortages, essential health benefits, Medicaid coverage, Medicare coverage and reimbursement, and Orphan Drug Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2011 · fourth_quarter · Q4
Medicare coverage and reimbursement, Medigap reform, IPAB, Medicaid coverage, bioequivalence, rare diseases, antibiotic incentives, progressive approvals, drug shortages, 340B, and essential health benefits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2011 · third_quarter · Q3
Medicare coverage and reimbursement, Medigap reform, IPAB, Medicaid coverage, bioequivalence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIROPHARMA INCORPORATED via VIROPHARMA INCORPORATED
2011 · third_quarter · RR
Minimum essential health benefits; Coverage/reimbursement/rebates under Medicaid and Medicare parts B and D; Drug approvals, shortages, safety, and cost containment; 340B Drug Pricing Program; Appropriations; Bioequivalence; Non-patent exclusivity; Orphan Drug Act; Prescription Drug User Fee Act; Corporate tax reform; Health insurance reform; Comparative effectiveness; Annual branded prescription drug fee; Medigap reform.